A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection
Phase of Trial: Phase II/III
Latest Information Update: 16 Mar 2018
At a glance
- Drugs PRO 140 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors CytoDyn
- 12 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 09 Aug 2017 According to a CytoDyn Inc. media release, enrollment has exceeded 100 patients in this trial.
- 10 Jun 2017 Biomarkers information updated